Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited has successfully completed the recruitment for its ACTION3 Phase 3 clinical trial, which evaluates the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS). The trial, which involves 286 adult patients, has shown promising interim results, with DMX-200 outperforming placebo in reducing proteinuria, a marker of kidney disease progression. The company plans to seek feedback from the FDA on trial endpoints and potential accelerated approval, positioning itself for regulatory submission and potential commercialization.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a biopharmaceutical company focused on developing innovative therapies for areas with unmet medical needs. The company is headquartered in Victoria, Australia, and is actively engaged in advancing its Phase 3 clinical asset in kidney disease.
Average Trading Volume: 1,183,625
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$360.2M
For a thorough assessment of DXB stock, go to TipRanks’ Stock Analysis page.